Jasmine is a 42-year-old Hispanic female with moderate to severe plaque psoriasis who recently expressed interest in participating in a clinical trial for a new biologic treatment. She has Fitzpatrick skin type V and is concerned about whether clinical trial data adequately represent patients with skin of color like herself. Her current medications include topical corticosteroids and emollients. She also speaks primarily Spanish and has limited experience with clinical research.

Question: As a pharmacist involved in clinical trial recruitment, which strategy from the VISIBLE trial would best support Jasmine’s enrollment and retention in the study?

Marcus is a 50-year-old Black male with moderate scalp psoriasis interested in a clinical trial evaluating guselkumab. He has a history of poor adherence to previous treatments and expresses mistrust toward medical research due to past experiences. The clinical trial site staff have limited experience working with skin of color populations.

Question: Which intervention aligned with the VISIBLE trial’s quality improvement framework would most effectively enhance Marcus’s participation and retention?

Dr. Lee is a pharmacist consultant advising a dermatology research team designing a new psoriasis trial. The team wants to ensure robust data collection relevant to patients with skin of color, including genetic and clinical outcomes. They plan to use standard erythema scoring methods but are unsure how to address pigmentary differences.

Question: Based on the VISIBLE trial findings, what is the best recommendation to improve assessment accuracy and inclusivity in this trial?